Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

RNA virus building blocks-miRNAs not included.

Aguado LC, tenOever B.

PLoS Pathog. 2018 May 31;14(5):e1006963. doi: 10.1371/journal.ppat.1006963. eCollection 2018 May. No abstract available.

2.

RNase III Nucleases and the Evolution of Antiviral Systems.

Aguado LC, tenOever BR.

Bioessays. 2018 Feb;40(2). doi: 10.1002/bies.201700173. Epub 2017 Dec 21. Review.

PMID:
29266287
3.

RNase III nucleases from diverse kingdoms serve as antiviral effectors.

Aguado LC, Schmid S, May J, Sabin LR, Panis M, Blanco-Melo D, Shim JV, Sachs D, Cherry S, Simon AE, Levraud JP, tenOever BR.

Nature. 2017 Jul 6;547(7661):114-117. doi: 10.1038/nature22990. Epub 2017 Jun 28.

4.

microRNA Function Is Limited to Cytokine Control in the Acute Response to Virus Infection.

Aguado LC, Schmid S, Sachs D, Shim JV, Lim JK, tenOever BR.

Cell Host Microbe. 2015 Dec 9;18(6):714-22. doi: 10.1016/j.chom.2015.11.003.

5.

Drosha as an interferon-independent antiviral factor.

Shapiro JS, Schmid S, Aguado LC, Sabin LR, Yasunaga A, Shim JV, Sachs D, Cherry S, tenOever BR.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7108-13. doi: 10.1073/pnas.1319635111. Epub 2014 Apr 28.

6.

Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P.

Sci Transl Med. 2013 Aug 14;5(198):198ra107. doi: 10.1126/scitranslmed.3006637.

Supplemental Content

Loading ...
Support Center